Takeda recently announced favorable results from a phase 3 study of TAK-755, the company’s investigational enzyme replacement therapy for an ultra-rare blood disorder known as congenital thrombotic thrombocytopenic purpura (cTTP).
↧
Channel:
National Bleeding Disorders Foundation - for all blood and bleeding disorders
X
Are you the publisher?
Claim or
contact us
about this channel.
X
0
Channel Details:
- Title: National Bleeding Disorders Foundation - for all blood and bleeding disorders
- Channel Number: 48658386
- Language: English
- Registered On: July 17, 2015, 4:00 am
- Number of Articles: 637
- Latest Snapshot: July 4, 2025, 7:20 am
- RSS URL: http://www.hemophilia.org/rss.xml?destination=nhfweb/resource/staticpages/menu0/menu4/menu306/menu308/wd08_tp_medigap.pdf
- Publisher: https://www.bleeding.org/
- Description:
- Catalog: //hemophilia83.rssing.com/catalog.php?indx=48658386
© 2025 //www.rssing.com